{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:00:35Z","timestamp":1785538835318,"version":"3.56.0"},"reference-count":193,"publisher":"Frontiers Media SA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2014.00629","type":"journal-article","created":{"date-parts":[[2014,12,12]],"date-time":"2014-12-12T07:04:56Z","timestamp":1418367896000},"source":"Crossref","is-referenced-by-count":76,"title":["Is Dosing of Therapeutic Immunoglobulins Optimal? A Review of a Three-Decade Long Debate in Europe"],"prefix":"10.3389","volume":"5","author":[{"given":"Jacqueline","family":"Kerr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Quinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Eibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Chapel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Sp\u00c3\u00a4th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. A. Carrock","family":"Sewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulgabar","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo N.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taco W.","family":"Kuijpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Hartmut","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2014,12,12]]},"reference":[{"key":"B1","first-page":"359","article-title":"Global plasma demand in 2015","volume-title":"Pharmaceuticals Policy and Law Rare Diseases: Focus on Plasma Related Disorders","author":"Robert","year":"2009"},{"issue":"2","key":"B2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2174\/187231211795305302","article-title":"Serum trough IgG level and annual intravenous immunoglobulin dose are not related to body size in patients on regular replacement therapy","volume":"5","author":"Khan","year":"2011","journal-title":"Drug Metab Lett"},{"issue":"9","key":"B3","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2146\/ajhp110744","article-title":"Impact of ideal body weight dosing for all inpatient i.v. immune globulin indications","volume":"70","author":"Rocchio","year":"2013","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"B4","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1007\/s10875-012-9720-1","article-title":"Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis","volume":"32","author":"Abolhassani","year":"2012","journal-title":"J Clin Immunol"},{"issue":"Suppl 2","key":"B5","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1007\/s10875-012-9853-2","article-title":"Why I use subcutaneous immunoglobulin (SCIG)","volume":"33","author":"Shapiro","year":"2013","journal-title":"J Clin Immunol"},{"issue":"2","key":"B6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10875-011-9631-6","article-title":"Higher doses of subcutaneous IgG reduce resource utilization in patients with primary immunodeficiency","volume":"32","author":"Haddad","year":"2012","journal-title":"J Clin Immunol"},{"issue":"12","key":"B7","first-page":"768","article-title":"Calculating the dose of subcutaneous immunoglobulin for primary immunodeficiency disease in patients switched from intravenous to subcutaneous immunoglobulin without the use of a dose-adjustment coefficient","volume":"38","author":"Fadeyi","year":"2013","journal-title":"P T"},{"issue":"8","key":"B8","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1002\/eji.201444700","article-title":"European consensus proposal for immunoglobulin therapies","volume":"44","author":"Sewell","year":"2014","journal-title":"Eur J Immunol"},{"issue":"6","key":"B9","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics"},{"key":"B10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.7326\/0003-4819-101-4-435","article-title":"Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease","volume":"101","author":"Cunningham-Rundles","year":"1984","journal-title":"Ann Intern Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1006\/clim.1999.4725","article-title":"Common variable immunodeficiency: clinical and immunological features of 248 patients","volume":"92","author":"Cunningham-Rundles","year":"1999","journal-title":"Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1365-2249.2009.04029.x","article-title":"Intravenous immunoglobulins. Current understanding and future directions","volume":"1","author":"Jolles","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2141.2009.07669.x","article-title":"Update in understanding common variable immuno-deficiency disorders (CVIDs) and the management of patients with these conditions","volume":"145","author":"Chapel","year":"2009","journal-title":"Br J Haematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/0002-9343(84)90324-3","article-title":"Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases","volume":"76","author":"Ochs","year":"1984","journal-title":"Am J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","article-title":"Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies","volume":"137","author":"Orange","year":"2010","journal-title":"Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1365-2249.2012.04594.x","article-title":"Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy","volume":"169","author":"Orange","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.jaci.2010.02.040","article-title":"Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years","volume":"125","author":"Lucas","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"B18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaci.2013.12.1077","article-title":". Clinical picture and treatment of 2212 patients with common variable immunodeficiency","volume":"134","author":"Gathmann","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10875-011-9511-0","article-title":"Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study","volume":"31","author":"Quinti","year":"2011","journal-title":"J Clin Immunol"},{"issue":"6 Suppl","key":"B20","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.anai.2013.09.014","article-title":"Illustrative cases on individualizing immunoglobulin therapy in primary immunodeficiency disease","volume":"111","author":"Bonagura","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"B21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3810\/pgm.2013.11.2712","article-title":"Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency","volume":"125","author":"Landersdorfer","year":"2013","journal-title":"Postgrad Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s13554-014-0018-0","article-title":"Enhancing patient flexibility of subcutaneous immunoglobulin G dosing: pharmacokinetic outcomes of various maintenance and loading regimens in the treatment of primary immunodeficiency","volume":"4","author":"Sidhu","year":"2014","journal-title":"Biol Ther"},{"issue":"8","key":"B23","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s10875-014-0096-2","article-title":"Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies","volume":"34","author":"Soler-Palac\u00c3\u00adn","year":"2014","journal-title":"J Clin Immunol"},{"issue":"7","key":"B24","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s10875-014-0081-9","article-title":"Adequate patient\u00e2\u20ac\u2122s outcome achieved with short immunoglobulin replacement intervals in severe antibody deficiencies","volume":"34","author":"Milito","year":"2014","journal-title":"J Clin Immunol"},{"key":"B25","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMp1207437","article-title":"Getting the methods right-the foundation of patient-centered outcomes research","volume":"367","author":"Gabriel","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"B26","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/cei.12002","article-title":"Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor","volume":"171","author":"Gouilleux-Gruart","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s15010-012-0323-9","article-title":"Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients","volume":"40","author":"Schroeder","year":"2012","journal-title":"Infection"},{"key":"B28","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1128\/CDLI.11.6.1158-1164.2004","article-title":"Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations","volume":"11","author":"Mikolajczyk","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s10875-010-9423-4","article-title":"Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency","volume":"30","author":"Hagan","year":"2010","journal-title":"J Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2249.2011.04387.x","article-title":"Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy","volume":"164","author":"Kaveri","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2249.2009.04022.x","article-title":"Intravenous immunoglobulins \u00e2\u20ac\u201c understanding properties and mechanisms","volume":"158","author":"Durandy","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jaci.2010.10.030","article-title":"The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders","volume":"127","author":"Ballow","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"3\u00e2\u20ac\u201c4","key":"B33","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ejps.2009.02.014","article-title":"Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency","volume":"37","author":"Wasserman","year":"2009","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"B34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.anai.2013.04.015","article-title":"Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis","volume":"111","author":"Shapiro","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"B35","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jaci.2012.06.021","article-title":"Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency","volume":"130","author":"Wasserman","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"B36","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s40265-013-0094-3","article-title":"Subcutaneous immunoglobulins for primary and secondary immunodeficiencies: an evidence-based review","volume":"73","author":"Lingman-Framme","year":"2013","journal-title":"Drugs"},{"issue":"5","key":"B37","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1586\/1744666X.2014.902314","article-title":"Secondary antibody deficiency","volume":"10","author":"Duraisingham","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"issue":"Suppl 2","key":"B38","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1097\/01.all.0000433132.16436.b5","article-title":"Management of secondary immune deficiencies: what is the role of immunoglobulins?","volume":"13","author":"Mouthon","year":"2013","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"9","key":"B39","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.amjmed.2006.12.013","article-title":"Evaluation of the adult with suspected immunodeficiency (review)","volume":"120","author":"Azar","year":"2007","journal-title":"Am J Med"},{"issue":"14","key":"B40","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1056\/NEJM198810063191403","article-title":"Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative group for the study of immunoglobulin in chronic lymphocytic leukemia","volume":"319","author":"Controlled Clinical Trial Cooperative Group","year":"1988","journal-title":"N Engl J Med"},{"issue":"2","key":"B41","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood.V73.2.366.366","article-title":"Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors","volume":"73","author":"Griffiths","year":"1989","journal-title":"Blood"},{"issue":"1","key":"B42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2257.1995.tb00322.x","article-title":"Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogamma-globulinaemia","volume":"17","author":"Boughton","year":"1995","journal-title":"Clin Lab Haematol"},{"issue":"2","key":"B43","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/cei.12053","article-title":"Specific antibody deficiency in children with recurrent respiratory infections: a controlled study with follow-up","volume":"172","author":"Ruuskanen","year":"2013","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"B44","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.vaccine.2007.10.053","article-title":"Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia","volume":"26","author":"Sinisalo","year":"2007","journal-title":"Vaccine"},{"issue":"11","key":"B45","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.vaccine.2008.01.010","article-title":"Efficacy of pneumococcal vaccination in chronic lymphocytic leukemia: should we rely on surrogate markers?","volume":"26","author":"Smolej","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"B46","first-page":"121","article-title":"Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIg) in chronic lymphocytic leukemia. Results of a crossover study","volume":"81","author":"Molica","year":"1996","journal-title":"Haematologica"},{"issue":"2","key":"B47","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1600-0609.1994.tb01874.x","article-title":"Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin","volume":"53","author":"Jurlander","year":"1994","journal-title":"Eur J Haematol"},{"issue":"8905","key":"B48","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK group for immunoglobulin replacement therapy in multiple myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet"},{"issue":"6","key":"B49","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1128\/CVI.00021-11","article-title":"Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom\u00e2\u20ac\u2122s macroglobulinemia, and monoclonal gammopathy of undetermined significance","volume":"18","author":"Karlsson","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"B50","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1080\/10428190902856824","article-title":"Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis","volume":"50","author":"Raanani","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"B51","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJM199009133231103","article-title":"Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation","volume":"323","author":"Sullivan","year":"1990","journal-title":"N Engl J Med"},{"issue":"1","key":"B52","doi-asserted-by":"publisher","first-page":"8","DOI":"10.7326\/0003-4819-139-1-200307010-00007","article-title":"Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial","volume":"139","author":"Cordonnier","year":"2003","journal-title":"Ann Intern Med"},{"issue":"5","key":"B53","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1200\/JCO.2008.16.8450","article-title":"Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"27","author":"Raanani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"B54","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/j.1399-3046.2012.01783.x","article-title":"Subcutaneous IgG replacement after pediatric SCT","volume":"16","author":"Sundin","year":"2012","journal-title":"Pediatr Transplant"},{"issue":"2","key":"B55","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1056\/NEJM199107113250201","article-title":"Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection","volume":"325","author":"The National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group","year":"1991","journal-title":"N Engl J Med"},{"issue":"18","key":"B56","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1056\/NEJM199411033311802","article-title":"A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group","volume":"331","author":"Spector","year":"1994","journal-title":"N Engl J Med"},{"issue":"2","key":"B57","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"B58","doi-asserted-by":"publisher","first-page":"e37626","DOI":"10.1371\/journal.pone.0037626","article-title":"Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides","volume":"7","author":"Venhoff","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"B59","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3109\/08916934.2013.798652","article-title":"B cell homeostasis is disturbed by immunosuppressive therapies in patients with ANCA-associated vasculitides","volume":"46","author":"Thiel","year":"2013","journal-title":"Autoimmunity"},{"issue":"10","key":"B60","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1111\/ajt.12401","article-title":"What is the impact of hypogamma-globulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis","volume":"13","author":"Florescu","year":"2013","journal-title":"Am J Transplant"},{"issue":"1","key":"B61","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/ki.1993.234","article-title":"Infectious disease complications of renal transplantation (review)","volume":"44","author":"Rubin","year":"1993","journal-title":"Kidney Int"},{"issue":"6","key":"B62","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.intimp.2008.09.013","article-title":"Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation","volume":"9","author":"Sarmiento","year":"2009","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"B63","doi-asserted-by":"publisher","first-page":"E277","DOI":"10.1111\/j.1399-0012.2012.01653.x","article-title":"Restoration of humoral immunity after intravenous immunoglobulin replacement therapy in heart recipients with post-transplant antibody deficiency and severe infections","volume":"26","author":"Carbone","year":"2012","journal-title":"Clin Transplant"},{"issue":"12","key":"B64","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1136\/jech-2011-200168","article-title":"Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses","volume":"66","author":"Wotton","year":"2012","journal-title":"J Epidemiol Community Health"},{"issue":"5","key":"B65","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients","volume":"82","author":"Cervera","year":"2003","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"B66","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/1529-0131(200104)45:2191::AID-ANR1733.3.CO;2-U","article-title":"Systemic lupus erythematosus in three ethnic groups. VII[correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group","volume":"45","author":"Alarc\u00c3\u00b3n","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"9","key":"B67","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1191\/0961203303lu452oa","article-title":"Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome","volume":"12","author":"Edwards","year":"2003","journal-title":"Lupus"},{"issue":"2","key":"B68","first-page":"273","article-title":"Depression of immune competence by phenytoin and carbamazepine. Studies in vivo and in vitro","volume":"20","author":"Sorrell","year":"1975","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"B69","first-page":"423","article-title":"Immunological study of IgA deficiency during anticonvulsant therapy in epileptic patients","volume":"53","author":"Matsuoka","year":"1983","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"B70","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/j.jaci.2013.01.018","article-title":"Inhibition of human B-cell development into plasmablasts by histone deacetylase inhibitor valproic acid","volume":"131","author":"Kienzler","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"8232","key":"B71","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"issue":"8924","key":"B72","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S0140-6736(94)92205-5","article-title":"Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura","volume":"344","author":"Blanchette","year":"1994","journal-title":"Lancet"},{"issue":"11","key":"B73","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"16","key":"B74","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American society of hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"issue":"3","key":"B75","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2450\/2014.0185-13","article-title":"Efficacy of combined intravenous immunoglobulins and steroids in children with primary immune thrombocytopenia and persistent bleeding symptoms","volume":"12","author":"Parodi","year":"2014","journal-title":"Blood Transfus"},{"issue":"5","key":"B76","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/MBC.0b013e32835e5337","article-title":"A comparison of intravenous immunoglobulin (2 g\/kg totally) and single doses of anti-D immunoglobulin at 50 \u00ce\u00bcg\/kg, 75 \u00ce\u00bcg\/kg in newly diagnosed children with idiopathic thrombocytopenic purpura: Ankara hospital experience","volume":"24","author":"Alioglu","year":"2013","journal-title":"Blood Coagul Fibrinolysis"},{"key":"B77","first-page":"143","article-title":"Efficacy of very low-dose (200 mg\/kg\/d) with short-term intravenous immunoglobulin G therapy according to individual response of acute immune thrombocytopenic purpura in childhood","volume":"13","author":"Lee","year":"2006","journal-title":"Clin Pediatr Hematol Oncol"},{"key":"B78","first-page":"611","article-title":"Very low-dose intravenous immunoglobulin for treatment of immune thrombocytopenic purpura","volume":"50","author":"Dua","year":"2013","journal-title":"Indian Pediatr"},{"issue":"8","key":"B79","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s40273-014-0171-9","article-title":"A cost-effectiveness study of intravenous immunoglobulin in childhood idiopathic thrombocytopenia purpura patients with life-threatening bleeding","volume":"32","author":"Sruamsiri","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"B80","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40258-013-0044-y","article-title":"Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland","volume":"11","author":"Lee","year":"2013","journal-title":"Appl Health Econ Health Policy"},{"issue":"2","key":"B81","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3111\/13696998.2012.756400","article-title":"Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Qu\u00c3\u00a9bec, Canada","volume":"16","author":"Pettigrew","year":"2013","journal-title":"J Med Econ"},{"issue":"5","key":"B82","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s12185-014-1551-9","article-title":"Identification of predictive factors for response to intravenous immunoglobulin treatment in children with immune thrombocytopenia","volume":"99","author":"Morimoto","year":"2014","journal-title":"Int J Hematol"},{"issue":"4","key":"B83","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1442-200X.2012.03606.x","article-title":"Idiopathic thrombocytopenic purpura in childhood: twenty years of experience in a single center","volume":"54","author":"Stiakaki","year":"2012","journal-title":"Pediatr Int"},{"issue":"4","key":"B84","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/jth.12524","article-title":"Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study","volume":"12","author":"Peng","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"1","key":"B85","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/MBC.0b013e328359bc3b","article-title":"Fc\u00ce\u00b3RIIa and Fc\u00ce\u00b3RIIIa polymorphisms in childhood primary immune thrombocytopenia: implications for disease pathogenesis and outcome","volume":"24","author":"Papagianni","year":"2013","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"3","key":"B86","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1182\/blood-2007-03-079913","article-title":"Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura","volume":"111","author":"Breunis","year":"2008","journal-title":"Blood"},{"issue":"8411","key":"B87","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S0140-6736(84)91504-6","article-title":"High-dose intravenous gammaglobulin for Kawasaki disease","volume":"2","author":"Furusho","year":"1984","journal-title":"Lancet"},{"issue":"23","key":"B88","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1056\/NEJM199106063242305","article-title":"A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome","volume":"324","author":"Newburger","year":"1991","journal-title":"N Engl J Med"},{"issue":"1","key":"B89","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/archdischild-2012-302841","article-title":"Management of Kawasaki disease","volume":"99","author":"Eleftheriou","year":"2014","journal-title":"Arch Dis Child"},{"issue":"9","key":"B90","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/FPC.0b013e328363686e","article-title":"Fc\u00ce\u00b3R gene copy number in Kawasaki disease and intravenous immunoglobulin treatment response","volume":"23","author":"Makowsky","year":"2013","journal-title":"Pharmacogenet Genomics"},{"issue":"9","key":"B91","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.humimm.2010.06.008","article-title":"Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance","volume":"71","author":"Fury","year":"2010","journal-title":"Hum Immunol"},{"issue":"12","key":"B92","doi-asserted-by":"publisher","first-page":"e81448","DOI":"10.1371\/journal.pone.0081448","article-title":"Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G","volume":"8","author":"Ogata","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"B93","doi-asserted-by":"publisher","first-page":"e63399","DOI":"10.1371\/journal.pone.0063399","article-title":"Comparative effectiveness of intravenous immunoglobulin for children with Kawasaki disease: a nationwide cohort study","volume":"8","author":"Lin","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"B94","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1067\/mpd.2000.104815","article-title":"Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset","volume":"137","author":"Fukunishi","year":"2000","journal-title":"J Pediatr"},{"issue":"2","key":"B95","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jpeds.2006.03.050","article-title":"Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease","volume":"149","author":"Egami","year":"2006","journal-title":"J Pediatr"},{"issue":"22","key":"B96","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1161\/CIRCULATIONAHA.105.592865","article-title":"Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease","volume":"113","author":"Kobayashi","year":"2006","journal-title":"Circulation"},{"issue":"2","key":"B97","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/heartjnl-2012-302126","article-title":"Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis","volume":"99","author":"Chen","year":"2013","journal-title":"Heart"},{"issue":"4","key":"B98","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3899\/jrheum.110877","article-title":"Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series","volume":"39","author":"Mori","year":"2012","journal-title":"J Rheumatol"},{"issue":"5","key":"B99","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jpeds.2004.12.022","article-title":"Infliximab treatment for refractory Kawasaki syndrome","volume":"146","author":"Burns","year":"2005","journal-title":"J Pediatr"},{"issue":"1","key":"B100","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1442-200X.2011.03487.x","article-title":"Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease","volume":"54","author":"Hokosaki","year":"2012","journal-title":"Pediatr Int"},{"issue":"2","key":"B101","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1542\/peds.63.2.175","article-title":"Kawasaki disease: effect of treatment on coronary artery involvement","volume":"63","author":"Kato","year":"1979","journal-title":"Pediatrics"},{"issue":"6","key":"B102","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1542\/peds.2004-2182","article-title":"Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association","volume":"114","author":"Newburger","year":"2004","journal-title":"Pediatrics"},{"issue":"7","key":"B103","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1056\/NEJMoa061235","article-title":"Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease","volume":"356","author":"Newburger","year":"2007","journal-title":"N Engl J Med"},{"issue":"9826","key":"B104","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/S0140-6736(11)61930-2","article-title":"Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial","volume":"379","author":"Kobayashi","year":"2012","journal-title":"Lancet"},{"issue":"9826","key":"B105","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(12)60196-2","article-title":"Management of Kawasaki disease: corticosteroids revisited","volume":"379","author":"Son","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"B106","doi-asserted-by":"publisher","first-page":"831.e\u00e2\u20ac\u201c5.e","DOI":"10.1016\/j.jpeds.2010.10.031","article-title":"Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance","volume":"158","author":"Sleeper","year":"2011","journal-title":"J Pediatr"},{"issue":"17","key":"B107","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barr\u00c3\u00a9 syndrome. Dutch Guillain-Barr\u00c3\u00a9 Study Group","volume":"326","author":"van der Mech\u00c3\u00a9","year":"1992","journal-title":"N Engl J Med"},{"issue":"1","key":"B108","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1212\/WNL.46.1.100","article-title":"Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barr\u00c3\u00a9 syndrome","volume":"46","author":"Bril","year":"1996","journal-title":"Neurology"},{"issue":"9047","key":"B109","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00c3\u00a9 syndrome","volume":"349","author":"Plasma Exchange\/Sandoglobulin Guillain-Barr\u00c3\u00a9 Syndrome Trial Group","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"B110","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1177\/088307380001500308","article-title":"New concepts of Guillain-Barr\u00c3\u00a9 syndrome","volume":"15","author":"Asbury","year":"2000","journal-title":"J Child Neurol"},{"issue":"3","key":"B111","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1021\/pr401213z","article-title":"IgG Fc N-glycosylation in Guillain-Barr\u00c3\u00a9 syndrome treated with immunoglobulins","volume":"13","author":"Fokkink","year":"2014","journal-title":"J Proteome Res"},{"key":"B112","doi-asserted-by":"publisher","first-page":"CD002063","DOI":"10.1002\/14651858.CD002063.pub5","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00c3\u00a9 syndrome","volume":"7","author":"Hughes","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"B113","doi-asserted-by":"publisher","first-page":"CD001446","DOI":"10.1002\/14651858.CD001446.pub4","article-title":"Corticosteroids for Guillain-Barr\u00c3\u00a9 syndrome","volume":"8","author":"Hughes","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"B114","volume-title":"Expert Consensus Statements on the Use of IVIg in Neurology, Asia Pacifique IVIgAdvisory Board","author":"Kornberg","year":"2004"},{"issue":"2","key":"B115","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/jnnp.71.2.235","article-title":"Intravenous immune globulins in patients with Guillain-Barr\u00c3\u00a9 syndrome and contraindications to plasma exchange: 3 days versus 6 days","volume":"71","author":"Raphael","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"B116","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1542\/peds.2004-1324","article-title":"Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barr\u00c3\u00a9 syndrome: a randomized trial","volume":"116","author":"Korinthenberg","year":"2005","journal-title":"Pediatrics"},{"issue":"5","key":"B117","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ana.21737","article-title":"Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barr\u00c3\u00a9 syndrome","volume":"66","author":"Kuitwaard","year":"2009","journal-title":"Ann Neurol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"CD002063","DOI":"10.1002\/14651858.CD002063.pub6","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00c3\u00a9 syndrome","volume":"9","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"9404","key":"B119","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","article-title":"Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barr\u00c3\u00a9 syndrome: randomised trial","volume":"363","author":"van Koningsveld","year":"2004","journal-title":"Lancet"},{"issue":"9","key":"B120","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/jnnp.2006.102731","article-title":"Treatment of Guillain-Barr\u00c3\u00a9 syndrome with mycophenolate mofetil: a pilot study","volume":"78","author":"Garssen","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"B121","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1212\/01.WNL.0000092019.53628.88","article-title":"A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barr\u00c3\u00a9 syndrome","volume":"61","author":"Pritchard","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"B122","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/1531-8249(200003)47:3314::AID-ANA63.0.CO;2-C","article-title":"Clinical features and response to treatment in Guillain-Barr\u00c3\u00a9 syndrome associated with antibodies to GM1b ganglioside","volume":"47","author":"Yuki","year":"2000","journal-title":"Ann Neurol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"CD001797","DOI":"10.1002\/14651858.CD001797.pub3","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"12","author":"Eftimov","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"B124","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/WCO.0b013e328363bfa4","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: update on clinical features, phenotypes and treatment options","volume":"26","author":"Eftimov","year":"2013","journal-title":"Curr Opin Neurol"},{"issue":"10","key":"B125","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1136\/jnnp.2004.052282","article-title":"T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy","volume":"76","author":"Csurhes","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"B126","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1085-9489.2006.00061.x","article-title":"Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"11","author":"Hughes","year":"2006","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"B127","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1529-8027.2008.00158.x","article-title":"Impairment of circulating CD4+CD25+ regulatory T cells in patients with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"13","author":"Chi","year":"2008","journal-title":"J Peripher Nerv Syst"},{"issue":"8","key":"B128","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3109\/08916930903140907","article-title":"Circulating subsets and CD4(+)CD25(+) regulatory T cell function in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"42","author":"Sanvito","year":"2009","journal-title":"Autoimmunity"},{"issue":"6","key":"B129","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1212\/WNL.0b013e318245d250","article-title":"CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"78","author":"Schneider-Hohendorf","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"B130","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0165-5728(94)00185-Q","article-title":"Increased frequencies of HPRT mutant T lymphocytes in patients with Guillain-Barr\u00c3\u00a9 syndrome and chronic inflammatory demyelinating polyneuropathy: further evidence for a role of T cells in the etiopathogenesis of peripheral demyelinating diseases","volume":"58","author":"Van den Berg","year":"1995","journal-title":"J Neuroimmunol"},{"issue":"2","key":"B131","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ana.1088","article-title":"Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"50","author":"Hughes","year":"2001","journal-title":"Ann Neurol"},{"issue":"6","key":"B132","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1474-4422(12)70093-5","article-title":"Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial","volume":"11","author":"Nobile-Orazio","year":"2012","journal-title":"Lancet Neurol"},{"issue":"7","key":"B133","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1001\/archneurol.2010.105","article-title":"Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"67","author":"Latov","year":"2010","journal-title":"Arch Neurol"},{"issue":"2","key":"B134","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"issue":"3","key":"B135","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1474-4422(10)70021-1","article-title":"Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial","volume":"9","author":"van Schaik","year":"2010","journal-title":"Lancet Neurol"},{"issue":"6","key":"B136","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/ana.410360607","article-title":"A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"36","author":"Dyck","year":"1994","journal-title":"Ann Neurol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"CD002062","DOI":"10.1002\/14651858.CD002062.pub2","article-title":"Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"8","author":"Hughes","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"B138","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1471-2377-14-72","article-title":"Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern","volume":"14","author":"Eftimov","year":"2014","journal-title":"BMC Neurol"},{"issue":"8","key":"B139","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/jnnp-2012-304670","article-title":"Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy","volume":"84","author":"Kuitwaard","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1\u00e2\u20ac\u201c2","key":"B140","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000350287","article-title":"Optimization of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy evaluated by grip strength measurement","volume":"70","author":"Kokubun","year":"2013","journal-title":"Eur Neurol"},{"issue":"4","key":"B141","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1529-8027.2006.00105.x","article-title":"Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy","volume":"11","author":"Rajabally","year":"2006","journal-title":"J Peripher Nerv Syst"},{"issue":"8","key":"B142","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1007\/s00415-013-6938-7","article-title":"Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens?","volume":"260","author":"Rajabally","year":"2013","journal-title":"J Neurol"},{"issue":"2","key":"B143","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3810\/pgm.2013.03.2619","article-title":"Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders","volume":"125","author":"Broyles","year":"2013","journal-title":"Postgrad Med"},{"key":"B144","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1478-7547-8-14","article-title":"Cost-utility of intravenous immunoglobulin (IVIG) compared with corticosteroids for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in Canada","volume":"8","author":"Blackhouse","year":"2010","journal-title":"Cost Eff Resour Alloc"},{"issue":"3","key":"B145","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/mus.20909","article-title":"Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy","volume":"37","author":"Lee","year":"2008","journal-title":"Muscle Nerve"},{"issue":"5","key":"B146","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/ene.12080","article-title":"Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"20","author":"Markvardsen","year":"2013","journal-title":"Eur J Neurol"},{"issue":"1","key":"B147","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/mus.20664","article-title":"Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial","volume":"35","author":"Gorson","year":"2007","journal-title":"Muscle Nerve"},{"issue":"8","key":"B148","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1212\/WNL.0b013e3181d1a862","article-title":"Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"74","author":"Hughes","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"B149","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S1474-4422(08)70299-0","article-title":"Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study","volume":"8","author":"RMC Trial Group","year":"2009","journal-title":"Lancet Neurol"},{"issue":"12","key":"B150","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/j.1468-1331.2011.03495","article-title":"Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis","volume":"18","author":"Cocito","year":"2011","journal-title":"Eur J Neurol"},{"issue":"6","key":"B151","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1136\/jnnp.2009.177576","article-title":"Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy","volume":"81","author":"Bedi","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"B152","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00415-009-5437-3","article-title":"Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy","volume":"257","author":"Marsh","year":"2010","journal-title":"J Neurol"},{"issue":"1","key":"B153","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ana.410240113","article-title":"A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside","volume":"24","author":"Pestronk","year":"1988","journal-title":"Ann Neurol"},{"issue":"Suppl 1","key":"B154","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1007\/s10875-010-9408-3","article-title":"Intravenous immunoglobulin treatment in multifocal motor neuropathy","volume":"30","author":"van der Pol","year":"2010","journal-title":"J Clin Immunol"},{"issue":"2","key":"B155","doi-asserted-by":"publisher","first-page":"CD004429","DOI":"10.1002\/14651858.CD004429.pub2","article-title":"Intravenous immunoglobulin for multifocal motor neuropathy","volume":"18","author":"van Schaik","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"B156","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1529-8027.2011.00330.x","article-title":"A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study","volume":"16","author":"Misbah","year":"2011","journal-title":"J Peripher Nerv Syst"},{"issue":"8","key":"B157","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.12968\/bjon.2012.21.Sup5.S21","article-title":"A comparison between intravenous and subcutaneous immunogobulin","volume":"21","author":"Braine","year":"2012","journal-title":"Br J Nurs"},{"issue":"1","key":"B158","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrneurol.2011.175","article-title":"Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies","volume":"8","author":"Vlam","year":"2011","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"B159","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/jnnp-2013-305755","article-title":"Sensitivity and predictive value of anti-GM1\/galactocerebroside IgM antibodies in multifocal motor neuropathy","volume":"85","author":"Nobile-Orazio","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"B160","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11940-013-0269-y","article-title":"Treatment of multifocal motor neuropathy","volume":"16","author":"Jinka","year":"2014","journal-title":"Curr Treat Options Neurol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"CD003217","DOI":"10.1002\/14651858.CD003217.pub4","article-title":"Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy","volume":"4","author":"Umapathi","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"B162","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1136\/jnnp-2013-306227","article-title":"Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy","volume":"85","author":"Vlam","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"B163","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1529-8027.2009.00218.x","article-title":"Subcutaneous immunoglobulin therapy for multifocal motor neuropathy","volume":"14","author":"Eftimov","year":"2009","journal-title":"J Peripher Nerv Syst"},{"issue":"Pt 8","key":"B164","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1093\/brain\/awm144","article-title":"Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial","volume":"130","author":"Piepers","year":"2007","journal-title":"Brain"},{"issue":"3","key":"B165","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1529-8027.2010.00270.x","article-title":"An open-label trial of rituximab (Rituxan\u00c2\u00ae) in multifocal motor neuropathy","volume":"15","author":"Chaudhry","year":"2010","journal-title":"J Peripher Nerv Syst"},{"issue":"11","key":"B166","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J Clin Invest"},{"issue":"8373","key":"B167","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S0140-6736(84)90469-0","article-title":"High-dose intravenous gammaglobulin for myasthenia gravis","volume":"1","author":"Gajdos","year":"1984","journal-title":"Lancet"},{"issue":"11","key":"B168","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","article-title":"Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial","volume":"62","author":"Gajdos","year":"2005","journal-title":"Arch Neurol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"CD002277","DOI":"10.1002\/14651858.CD002277.pub4","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"12","author":"Gajdos","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"B170","first-page":"e15","article-title":"Fetal and neonatal alloimmune thrombocytopenia","volume":"6","author":"Espinoza","year":"2013","journal-title":"Rev Obstet Gynecol"},{"issue":"3","key":"B171","doi-asserted-by":"publisher","first-page":"e002490","DOI":"10.1136\/bmjopen-2012-002490","article-title":"Fetal intracranial haemorrhages caused by fetal and neonatoal alloimmune thrombocytopenia: an observational cohort study of 43 cases from an international multicentre registry","volume":"3","author":"Tiller","year":"2013","journal-title":"BMJ Open"},{"key":"B172","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1056\/NEJM198811243192103","article-title":"Antenatal treatment of neonatal alloimmune thrombocytopenia","volume":"319","author":"Bussel","year":"1988","journal-title":"N Engl J Med"},{"key":"B173","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1365-2141.2006.06418.x","article-title":"Advances in the management of alloimmune thrombocytopenia","volume":"136","author":"Murphy","year":"2006","journal-title":"Br J Haematol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/pd.2779","article-title":"Fetal and neonatal alloimmune thrombocytopenia","volume":"31","author":"Kamphuis","year":"2011","journal-title":"Prenat Diagn"},{"issue":"4","key":"B175","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1479-828X.2012.01438.x","article-title":"Neonatal outcome in alloimmune thrombocytopenia after maternal treatment with intravenous immunoglobulin","volume":"52","author":"Cook","year":"2012","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"B176","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2450\/2014.0309-13","article-title":"Neonatal outcome in alloimmune thrombocytopenia after maternal treatment with intravenous immunoglobulin","volume":"19","author":"Van Der Lugt","year":"2014","journal-title":"Blood Transfus"},{"issue":"7","key":"B177","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1111\/trf.12671","article-title":"How do we treat fetal and neonatal alloimmune thrombocytopenia?","volume":"54","author":"Bertrand","year":"2014","journal-title":"Transfusion"},{"key":"B178","doi-asserted-by":"publisher","first-page":"CD004226","DOI":"10.1002\/14651858.CD004226.pub3","article-title":"Antenatal interventions for fetomaternal alloimmune thrombocytopenia (review)","volume":"5","author":"Rayment","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"18","key":"B179","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1182\/blood-2010-05-284919","article-title":"Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy","volume":"116","author":"Chen","year":"2010","journal-title":"Blood"},{"key":"B180","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1111\/j.1537-2995.2011.03480.x","article-title":"Toward a prophylaxis against fetal an neonatal alloimmune thrombocytopenia: induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model","volume":"52","author":"Tiller","year":"2012","journal-title":"Transfusion"},{"issue":"3","key":"B181","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1182\/blood-2013-02-481887","article-title":"Recombinant HPA-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: proof of principle in human volunteers","volume":"122","author":"Ghevaert","year":"2013","journal-title":"Blood"},{"issue":"3","key":"B182","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1182\/blood-2012-11-468561","article-title":"Inhibition of HPA-1a alloantibody-mediated platelet destruction by a deglycosylated anti-HPA-1a monoclonal antibody in mice: toward targeted treatment of fetal-alloimmune thrombocytopenia","volume":"122","author":"Bakchoul","year":"2013","journal-title":"Blood"},{"issue":"6","key":"B183","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/MOH.0b013e328358f86c","article-title":"Towards a prophylactic treatment of HPA-related foetal and neonatal alloimmune thrombocytopenia","volume":"19","author":"Kjeldsen-Kragh","year":"2012","journal-title":"Curr Opin Hematol"},{"issue":"4 Suppl","key":"B184","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1067\/mai.2001.117821","article-title":"Obstetric use of intravenous immuno-globulin: successes, failures, and promises","volume":"108","author":"Branch","year":"2001","journal-title":"Allergy Clin Immunol"},{"key":"B185","doi-asserted-by":"publisher","first-page":"CD008267","DOI":"10.1002\/14651858.CD008267.pub2","article-title":"Antenatal immunoglobulin for fetal red blood cell alloimmunization","volume":"5","author":"Wong","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"B186","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1007\/s10875-014-0024-5","article-title":"Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations","volume":"34","author":"Dalakas","year":"2014","journal-title":"J Clin Immunol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2008.0580","article-title":"Update of the guideline on the use of high-dose intravenous immunoglobulin in dermatology","author":"Enk","year":"2011","journal-title":"Eur Dermatol Forum"},{"issue":"10","key":"B188","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.autrev.2014.08.023","article-title":"Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study","volume":"13","author":"Danieli","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"4","key":"B189","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.rdc.2013.06.001","article-title":"Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies","volume":"39","author":"Rider","year":"2013","journal-title":"Rheum Dis Clin North Am"},{"key":"B190","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2340\/00015555-1471","article-title":"Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events","volume":"93","author":"Seidling","year":"2013","journal-title":"Acta Derm Venereol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12423","article-title":"Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies","author":"Barron","year":"2014","journal-title":"Int J Dermatol"},{"issue":"1","key":"B192","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.clim.2011.06.002","article-title":"Efficacy and safety of Hizentra(\u00c2\u00ae) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy","volume":"141","author":"Jolles","year":"2011","journal-title":"Clin Immunol"},{"key":"B193","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s13311-011-0096-3","article-title":"Immune mediated diseases and immunmodulation in the neurocritical care unit","volume":"9","author":"von Geldern","year":"2012","journal-title":"Neurotherapeutics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"deposited":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T09:27:33Z","timestamp":1650792453000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2014.00629\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,12]]},"references-count":193,"URL":"https:\/\/doi.org\/10.3389\/fimmu.2014.00629","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,12]]}}}